A randomized double-blind trial to measure the absorption characteristics of eicosapentaenoic acid and docosahexaenoic acid rich oil blend with natural lipid-based delivery system

Jennifer Chuang; David Briskey; Jennifer Dang; Arun Rajgopal; Amanda Rao

doi:10.1007/s10068-023-01466-z

A randomized double-blind trial to measure the absorption characteristics of eicosapentaenoic acid and docosahexaenoic acid rich oil blend with natural lipid-based delivery system

Food Sci Biotechnol. 2023 Dec 11;33(8):1957-1964. doi: 10.1007/s10068-023-01466-z. eCollection 2024 Jun.

Authors

Jennifer Chuang¹, David Briskey^{2

3}, Jennifer Dang¹, Arun Rajgopal¹, Amanda Rao^{2

3}

Affiliations

¹ Nutrilite Health Institute, Amway I&S, 5600 Beach Boulevard, Buena Park, CA 90622 USA.
² RDC Clinical, Brisbane, Australia.
³ School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Australia.

Abstract

A randomized, double-blinded trial with 65 subjects was conducted to compare the pharmacokinetics between PhytoMarineCelle (PM) that consists of eicosapentaenoic acid and docosahexaenoic acid (EPA + DHA) plus a self-emulsifying drug delivery system (SEDDS), and a standard EPA + DHA ethyl ester (SEE) that does not contain SEDDS. PM showed 1.6-fold greater plasma area under the curve (AUC) than SEE at 300 mg, although no significant difference was observed. PM showed a 3.1 and 3.2-fold (p < 0.05) greater plasma AUC than SEE at 500 mg and 1000 mg respectively. The concentration max (Cmax) of EPA + DHA did not change between PM and SEE at 300 mg. Cmax of PM was twofold greater than SEE at 500 mg and 1000 mg respectively. The Cmax of EPA + DHA achieved significant difference (p < 0.05) only with the 500 mg dose. The PM formulation increased the bioavailability of EPA + DHA by threefold compared to SEE at 500 and 1000 mg.

Keywords: Absorption enhancement; Bioavailability; DHA; EPA; Omega-3 fatty acid.